Skip to main content
TipRanks
Go Ultimate75% OFF

Sona Nanotech Inc (SONA) AI Stock Analysis

54 Followers
TSE:SONA

Sona Nanotech Inc

(CNQX:SONA)

Select Model
Rating:37Underperform
Price Target:CAD 0.25â–¼(-6.67% Downside)
Action:reiterated
Date:10/01/26

The overall score of 37 indicates extreme risk and poor current performance, driven by Sona Nanotech's pre-revenue status, severe equity deficit, and strongly bearish price momentum. While management has curtailed the cash burn rate slightly, the fundamental necessity for external dilutive financing to maintain daily operations remains a dominant and pressing concern.

Positive Factors
Proprietary Nanorod TechnologySona’s proprietary gold nanorod platform gives it a defined technology focus in diagnostics and life sciences. If the particles deliver the targeted sensitivity and performance benefits, they could support differentiated products, customer adoption, and licensing or supply opportunities over time.
Negative Factors
No Revenue GenerationZero reported revenue means the technology has not yet translated into commercial sales, leaving the business dependent on future adoption or financing. Until recurring product or partnership revenue emerges, operating losses and uncertainty around sustainable earnings remain fundamental concerns.

Sona Nanotech Inc (SONA) vs. iShares MSCI Canada ETF (EWC)

-60%-40%-20%0%20%40%TSE:SONA-48.08%EWC+21.04%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
CAD 33.16M
Dividend Yield
―
Average Volume (3M)
50.10K
Price to Earnings (P/E)
-12.6
Beta (1Y)
0.86
Revenue Growth
―
EPS Growth
24.65%
Country
Canada
Employees
8
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Sona Nanotech Inc Business Overview & Revenue Model

Company Description

Based in Halifax, Canada, Sona Nanotech Inc. is a life sciences company focused on nanotechnology. It develops and commercializes gold nanorod solutions primarily for diagnostic applications. Their product portfolio includes the Nanotech COVID-19 Lat...

How the Company Makes Money

Sona Nanotech’s primary monetization approach is expected to be the sale and supply of its proprietary gold nanorods (and potentially related reagents/materials) for use by diagnostics and life-sciences customers in assay development and production,...

Sona Nanotech Inc Financial Statement Overview

Summary

Sona Nanotech is a pre-revenue biotechnology company exhibiting severe financial distress. Despite narrowing net losses over the past few years, the complete lack of top-line revenue, significant operational cash burn, and a deeply negative equity deficit present critical solvency risks.

Income Statement

10Very Negative

Balance Sheet

8Very Negative

Cash Flow

15Very Negative
Financial statement breakdown
BreakdownTTMJan 2026Jan 2025Jan 2024Jan 2023Jan 2022
Income Statement
Total Revenue000000
Gross Profit-720.00K-720.00K-733.98K-457.00K-60.32K-65.59K
EBITDA-1.90M-2.72M-2.00M-2.02M-2.34M-10.38M
Net Income-2.44M-3.25M-2.70M-2.50M-2.36M-10.77M
Balance Sheet
Total Assets542.77K1.33M3.75M2.75M520.77K1.52M
Cash, Cash Equivalents and Short-Term Investments17.21K125.95K1.86M115.38K164.42K1.20M
Total Debt340.16K307.74K394.67K527.68K608.47K1.34M
Total Liabilities1.81M1.37M1.24M1.59M1.03M2.75M
Stockholders Equity-1.26M-38.78K2.51M1.16M-507.86K-1.22M
Cash Flow
Free Cash Flow-894.27K-1.96M-1.96M-1.26M-1.81M-3.81M
Operating Cash Flow-894.26K-1.96M-1.96M-1.26M-1.81M-3.81M
Investing Cash Flow00014.64K00
Financing Cash Flow521.44K228.43K3.70M1.20M7784.89M

Sona Nanotech Inc Technical Analysis

Technical Analysis SentimentNegative
Last Price0.27

Price Trends

50DMA0.32Negative
100DMA0.32Negative
200DMA0.33Negative

Market Momentum

MACD-0.01Negative
RSI43.22Neutral
STOCH30.00Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:SONA, the sentiment is Negative. The current price of 0.27 is below the 20-day moving average (MA) of 0.28, below the 50-day MA of 0.32, and below the 200-day MA of 0.33, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 43.22 is Neutral, neither overbought nor oversold. The STOCH value of 30.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:SONA.

Sona Nanotech Inc Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

TSE:SONA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
TSE:MIRTSE:MIR47NeutralCAD 24.56M-7.9512.68%―45.72%35.82%
TSE:EBMTSE:EBM46NeutralCAD 120.55M-564.5213.66%―36.59%43.33%
TSE:SONATSE:SONA37UnderperformCAD 33.16M-12.62448.05%――24.65%
TSE:BUXTSE:BUX37UnderperformCAD 44.72M-31.11-250.77%―-82.05%23.73%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%150%TSE:SONATSE:BUXTSE:EBMTSE:SZLS.HTSE:MIRTSE:ZYUSDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TSE:SONA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TSE:SONASona Nanotech, Inc0.27-0.24-47.06%
TSE:BUXBioMark Diagnostics0.420.0720.00%
TSE:EBMEastwood Bio-Medical Canada1.751.00133.33%
TSE:SZLS.HStagezero Life Sciences0.040.000.00%
TSE:MIRMedmira Inc0.04-0.04-50.00%
TSE:ZYUSZyus Life Sciences Corporation0.40-0.29-42.03%

Sona Nanotech Inc Corporate Events

Business Operations and StrategyExecutive/Board Changes

Sona Nanotech Elevates CTO and Grants Options to Fund Cancer Therapy Push

Positive
Oct 13, 2026

Sona Nanotech Inc. has appointed company co-founder and core technology co-inventor Dr. Kulbir Singh as Chief Technology Officer, formalizing his leadership role in advancing the firm’s Targeted Hyperthermia delivery system toward commercialization....

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 01, 2026